ReviewFrontiers in immunology2014
Radiation for Awakening the Dormant Immune System, a Promising Challenge to be Explored.
Review in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03486431 (A Phase I Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy (SABR) for Non-spine Bone & Lymph Node Oligometastates
Who cites it
24 citing papers in PubMed.
- Integrated management of immunotherapy and radiotherapy for patients with metastatic non-small cell lung cancer: a narrative review of current landscape and future directions.Translational lung cancer research · 2026Review
- Article
- Brachytherapy for targeting the immune system in cervical cancer patients.BMC immunology · 2023Article
- Review
- Abscopal Response in Metastatic Melanoma: Real-World Data of a Retrospective, Multicenter Study.Cancers · 2022Article
- Case Report: Chemotherapy and Radiotherapy Combined With DC-CIK for Pulmonary and Mediastinal Metastases From Nasopharyngeal Carcinoma.Frontiers in oncology · 2022Article
- Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect.International journal of molecular sciences · 2021Review
- Article
- Changes in peripheral immune cells after intraoperative radiation therapy in low-risk breast cancer.Journal of radiation research · 2021Article
- Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors.Cells · 2020Review
- HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity.OncoTargets and therapy · 2020Review
- Research Progress and Existing Problems for Abscopal Effect.Cancer management and research · 2020Review
- Enhancing the efficacy of immunotherapy using radiotherapy.Clinical & translational immunology · 2020Review
- Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies.Journal of hematology & oncology · 2019Review
- A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial).Radiation oncology (London, England) · 2018Article
- Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy.Frontiers in immunology · 2018Review
- Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer.Frontiers in immunology · 2017Article
- Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer.British journal of cancer · 2016Article
- Long-term survival consequent on the abscopal effect in a patient with multiple myeloma.BMJ case reports · 2016Article
- The Future of Combining Carbon-Ion Radiotherapy with Immunotherapy: Evidence and Progress in Mouse Models.International journal of particle therapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances that have been made in our understanding of cancer biology and immunology show that infiltrated immune cells and cytokines in the tumor microenvironment may play different functions that appear tightly related to clinical outcomes. Strategies aimed at interfering with the cross-talk between microenvironment tumor cells and their cellular partners have been considered for the development of new immunotherapies. These novel therapies target different cell components of the tumor microenvironment and importantly, they may be coupled and boosted with classical treatments, such as radiotherapy. In this work, we try to summarize recent data on the microenvironment impact of radiation therapy, from pre-clinical research to the clinic, while taking into account that this new knowledge will probably translate into indication and objective of radiation therapy changes in the next future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.